Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E53.75 EPS (ttm)1.20 Insider Own0.20% Shs Outstand1.67B Perf Week-1.81%
Market Cap107.50B Forward P/E28.15 EPS next Y2.29 Insider Trans-17.01% Shs Float1.66B Perf Month3.53%
Income2.00B PEG3.32 EPS next Q0.50 Inst Own72.60% Short Float1.56% Perf Quarter8.51%
Sales15.88B P/S6.77 EPS this Y-22.10% Inst Trans1.04% Short Ratio3.99 Perf Half Y26.40%
Book/sh8.95 P/B7.21 EPS next Y33.12% ROA6.00% Target Price65.90 Perf Year27.65%
Cash/sh4.46 P/C14.46 EPS next 5Y16.21% ROE13.20% 52W Range45.35 - 69.20 Perf YTD9.27%
Dividend1.48 P/FCF479.91 EPS past 5Y-5.90% ROI6.40% 52W High-8.61% Beta0.24
Dividend %2.29% Quick Ratio1.50 Sales past 5Y-3.30% Gross Margin76.20% 52W Low39.45% ATR1.33
Employees25000 Current Ratio1.70 Sales Q/Q-4.10% Oper. Margin22.20% RSI (14)41.94 Volatility1.95% 2.18%
OptionableYes Debt/Eq0.53 EPS Q/Q-97.70% Profit Margin12.60% Rel Volume1.15 Prev Close64.50
ShortableYes LT Debt/Eq0.49 EarningsApr 28 BMO Payout119.80% Avg Volume6.49M Price63.24
Recom2.30 SMA20-4.65% SMA500.39% SMA20014.13% Volume4,726,124 Change-1.95%
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
Sep-22-10Reiterated Deutsche Bank Buy $28 → $31.50
Sep-01-10Reiterated UBS Neutral $26 → $27
Apr-01-15 01:17PM  Midday Glance: Pharmaceuticals companies
10:23AM  Early Glance: Pharmaceuticals companies
10:06AM  Pfizers Global Established Pharmaceutical Segment
06:00AM  Roche open to alliances in hunt for cancer drug combinations Reuters
Mar-31-15 05:58PM  Final Glance: Pharmaceuticals companies
11:57AM  Health-care hedge fund Orbimed's top picks at MarketWatch
10:17AM  Millions To Be Made On...Generic Drugs? at Forbes
Mar-30-15 10:50AM  Bristol-Myers Squibb Is Re-Testing Its Breakout Level
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Mar-27-15 04:01PM  Pfizer: A Leading Pharmaceutical Company
02:50PM  Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
02:40PM  Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog
12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
11:14AM  Europe pushes back verdict on Bristol immune system cancer drug Reuters
10:40AM  Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28 at noodls
10:08AM  Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28 Business Wire
08:49AM  Europe postpones decision on Bristol immune system cancer drug Reuters
Mar-26-15 12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
08:55AM  Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog
Mar-25-15 03:51PM  Good time for investors to jump in: Pro
01:14PM  Science, patients driving rare disease drug research surge
Mar-24-15 03:33PM  Merck halts study in light of melanoma drugs success at Fortune
02:58PM  Hottest dividend stocks of 2015 at CNBC
01:10PM  Two Healthcare Stocks Provide Antidotes To Wild Market Swings at Forbes
10:37AM  Merck's Keytruda Bests Yervoy In Early Melanoma at Investor's Business Daily
10:00AM  Merck says melanoma drug meets goal; study halted
09:30AM  Bristol-Myers Squibb (BMY) Stock Price Target Increased at BMO at TheStreet
08:27AM  Bristol-Myers buys rights to Novo Nordisk immune system project
08:24AM  Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases at noodls
08:00AM  Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases Business Wire
Mar-23-15 02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
12:21PM  SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
10:32AM  Kleiner Perkins's Beth Seidenberg Says Immunotherapy Is Biotech Powerhouse at The Wall Street Journal
09:05AM  4 Pharmaceutical Stocks to Buy for Outperformance in 2015 at 24/7 Wall St.
12:00AM  Bristol, Sanofi and Novartis drugs to shine among 2015 launches Reuters
Mar-20-15 07:25AM  AstraZeneca Lags in Cancer Race
07:25AM  AstraZeneca Lags in Cancer Race Where Losing May Spur Buyout at Bloomberg
Mar-18-15 03:22PM  Celldex, Roche Ink Deal to Develop Kidney Cancer Drug - Analyst Blog
10:13AM  Hedge Funds Love These 5 Big Stocks -- but Should You? at TheStreet
08:30AM  A Decade Old Drug Launch In China With Important Insights Today at Forbes
Mar-17-15 10:52AM  Why These Could Be 2015's 10-Best Pharma Stocks at Investopedia
Mar-16-15 08:00AM  A True Fountain-Of-Youth Drug Combo? at Forbes
Mar-13-15 04:45PM  Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog
Mar-12-15 05:57PM  [$$] Bristol-Myers's Andreotti Got $27.1 Million in Compensation in 2014 at The Wall Street Journal
03:31PM  Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3 at noodls
03:21PM  FDA to review re-submitted Bristol-Myers hepatitis C drug
03:00PM  Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3 Business Wire
Mar-11-15 04:30PM  Johnson & Johnson: A Leading Pharmaceuticals Company
09:40AM  4 Top Pharmaceutical Stocks to Buy for Market Safety at 24/7 Wall St.
Mar-09-15 11:58AM  Investors Bet $100,000 Cancer Drug Prices Are Here to Stay
06:00AM  Investors Warm to $100,000 Cancer Drugs After $21 Billion Deal at Bloomberg
Mar-06-15 03:20PM  Bristol-Myers Oncology Drug Opdivo Label Expanded in U.S. - Analyst Blog
10:10AM  Stock Market News for March 06, 2015 - Market News
Mar-05-15 10:17PM  Bristol-Myers gets faster than expected approval for first immuno oncology drug
05:15PM  BMY battles lung cancer
04:45PM  Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog Zacks
04:15PM  AbbVie's Bid Ups Ante as Buyers Bet on Cancer Drugs Bloomberg
04:15PM  AbbVies Bid Ups Ante as Buyers Bet on Cancer Drugs: Real M&A at Bloomberg
12:58PM  FMHR Final Trade: HEDJ, MRVL & BMY CNBC
10:21AM  Bristol-Myers Squibb (BMY) Stock Continues Climb Today on $975M Prostate Cancer Vaccine Deal at TheStreet
08:00AM  From Goldman to Google, Companies Back Gay Marriage in Supreme Court Brief at Bloomberg
Mar-04-15 07:05PM  Bristol-Myers Hits 14-Year High On Big Cancer News at Investor's Business Daily +6.06%
06:11PM  Cramer: As the smoke clears, these stocks win big at CNBC
06:00PM  Prostate cancer vaccine nabbed by Bristol-Myers Squibb for potential $1 billion at bizjournals.com
05:57PM  FDA Approves Bristol-Myers Drug for Lung Cancer at The Wall Street Journal
05:23PM  Brazil to Reduce Taxes for Distributed Solar Energy Generation at Bloomberg
04:13PM  FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer Business Wire
03:47PM  Bristol-Myers Squibb: 'This Is the Fastest Approval I've Seen' at Barrons.com
03:30PM  CNBC update: Lung cancer drug approved CNBC
03:28PM  Bristol-Myers Lung Cancer Drug Opdivo Wins Speedy OK at Investor's Business Daily
02:57PM  U.S. FDA approves Bristol-Myers immunotherapy for lung cancer Reuters
02:35PM  Bristol-Myers Wins Early Approval to Use Opdivo for Lung Cancer at Bloomberg
02:33PM  Bristol-Myers Squibb Hits All-Time High Off FDA Approval For Expanded Use Of Opvido Benzinga
02:21PM  Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab) Business Wire
01:48PM  FDA approves Bristol-Myers Squibb's Opdivo to treat lung cancer at MarketWatch
01:47PM  Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer at TheStreet
01:44PM  US FDA approves Bristol-Myers immunotherapy for lung cancer Reuters
10:50AM  Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog Zacks
10:37AM  Bristol's $1 bln Bavarian deal may signal cancer vaccine revival Reuters
09:10AM  Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog Zacks
01:32AM  Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Thomson Reuters ONE
01:30AM  Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Business Wire
Mar-03-15 03:13PM  Bristol-Myers Files for New Indications for Yervoy, Opdivo - Analyst Blog Zacks
01:45PM  Calculating the cost basis for shares you sold Consumer Reports
12:57PM  Pharming for Yield at The Wall Street Journal
05:59AM  Hepatitis C cure rate of 97 per cent announced in study of patients co-infected with HIV given 12-week combination treatment of daclatasvir and sofosbuvir in ALLY-2 trial CNW Group
Mar-02-15 06:47PM  How A Strong Greenback Dollar Affects the Economy at Investopedia
04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
09:25AM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence Business Wire
Feb-27-15 11:11PM  [$$] Biotech Sector Addicted to M&A Drug at The Wall Street Journal
06:29PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
02:06PM  Biotech Sector Addicted to M&A Drug at The Wall Street Journal
01:34PM  U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer Business Wire
08:26AM  5 Top-Heavy Stocks to Sell: Oracle, Michael Kors and More at TheStreet
Feb-26-15 03:15PM  Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Reuters
03:15PM  ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir Business Wire
09:45AM  Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers at bizjournals.com
09:05AM  Exchange-traded funds that hold big pharma Market Realist
08:30AM  Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies Business Wire
Feb-25-15 12:57PM  Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug Benzinga
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM